DiabetologyNews.net

Diabetology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Cardiobase

Type 2 diabetes: efficacy, safety, and tolerability of oral Semaglutide added to Insulin with or without Metformin: The PIONEER 8 trial


The aim of study was to investigate the efficacy, safety, and tolerability of oral Semaglutide ( Rybelsus ) added to Insulin with or without Metformin.

Patients with type 2 diabetes uncontrolled on Insulin with or without Metformin were randomized to oral Semaglutide 3 mg ( N = 184 ), 7 mg ( N = 182 ), or 14 mg ( N = 181 ) or to placebo ( N = 184 ) in a 52-week, double-blind trial.

End points were change from baseline to week 26 in HbA1c ( primary ) and body weight ( confirmatory secondary ).
Two estimands were defined: treatment policy ( effect regardless of trial product discontinuation or rescue medication ) and trial product ( effect assuming trial product continuation without rescue medication ) in randomized patients.

Oral Semaglutide was superior to placebo in reducing HbA1c ( estimated treatment difference [ ETD ] –0.5% [ 95% CI –0.7, –0.3% ], –0.9% [ –1.1, –0.7% ], –1.2% [ –1.4, –1.0% ] for 3, 7, and 14 mg, respectively; P less than 0.001 ) and body weight ( ETD −0.9 kg [ 95% CI −1.8, −0.0 kg ], −2.0 kg [ −3.0, −1.0 kg ], −3.3 kg [ −4.2, 2.3 kg ]; P = 0.0392 for 3 mg, P less than or equal to 0.0001 for 7 and 14 mg ) at week 26 ( treatment policy estimand ).

Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral Semaglutide at weeks 26 and 52 ( both estimands ).

The most frequent adverse event with oral Semaglutide was nausea ( 11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate ).

In conclusion, oral Semaglutide was superior to placebo in reducing HbA1c and body weight when added to Insulin with or without Metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 ( GLP-1 ) receptor agonists. ( Xagena )

Zinman B et al, Diabetes Care 2019; dc190898.doi.org/10.2337/dc19-0898

XagenaMedicine_2019



Indietro